利福平对健康志愿者中SMO抑制剂glasdegib药代动力学的影响
该开放标签、固定序列、两周期1期研究在12名健康男性志愿者中评估强CYP3A诱导剂利福平对glasdegib药代动力学的影响。结果显示,利福平使glasdegib的AUCinf几何均值比降至29.66%(90%CI 26.17-33.62),Cmax几何均值比降至64.71%(90%CI 57.21-73.19),即AUCinf降低约70%、Cmax降低约35%。所有不良事件均为轻度。
要点
- 利福平使glasdegib AUCinf降低约70%,Cmax降低约35%。
- 合用利福平时glasdegib终末半衰期由13.39小时降至5.11小时。
- 所有不良事件均为轻度,研究期间缓解。
核心结论
- 利福平预期性地降低glasdegib的AUCinf约70%和Cmax约35%,提示强CYP3A诱导剂可显著减少glasdegib暴露。
研究设计与样本
- 开放标签、固定序列、两周期1期研究,纳入12名健康男性志愿者,单次口服glasdegib 100 mg,单独或经利福平600 mg每日一次预处理后给药,采用非房室分析计算药代动力学参数。
主要发现
- 单用glasdegib时AUCinf几何均值(%CV)为8145 ng·h/ml(23%),Cmax为703.2 ng/ml(19%)。
- 合用利福平时AUCinf和Cmax的调整几何均值比(90%CI)分别为29.66%(26.17-33.62)和64.71%(57.21-73.19)。
- 终末半衰期均值由13.39小时降至5.11小时,表观口服清除率几何均值由12.27 l/h升至41.38 l/h。
- Tmax中位数相似(1.50 vs 1.25小时)。
- 所有不良事件(n=29)均为轻度,研究结束时缓解。
临床怎么用
- 临床合用强CYP3A诱导剂如利福平时,需考虑glasdegib暴露显著降低,可能需调整剂量策略。
局限性
- 研究仅纳入12名健康男性志愿者,结果外推至患者人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This study aimed to evaluate the effect of a strong CYP3A inducer, rifampin, on glasdegib pharmacokinetics in healthy volunteers. METHODS: In an open-label, fixed-sequence, two-period Phase 1 study, subjects received a single 100-mg oral dose of glasdegib alone or following once-daily pre-treatment with 600 mg rifampin. Glasdegib pharmacokinetics were calculated using a noncompartmental analysis. RESULTS: Twelve healthy male volunteers (3 whites, 5 blacks and 4 others) were enrolled in the study. Mean age, weight, height and body mass index was 37.8 years, 83.0 kg, 177.3 cm and 26.5 kg (m2 ) -1 , respectively. When dosed alone, glasdegib geometric mean (% coefficient of variation) area under the plasma concentration-time curve from time zero to infinity (AUCinf ) was 8145 ng × h ml-1 (23%) and maximum observed concentration (Cmax ) was 703.2 ng ml-1 (19%). With rifampin, glasdegib AUCinf and Cmax decreased, with an adjusted geometric mean ratio (90% confidence interval) 29.66% (26.17-33.62) for AUCinf and 64.71% (57.21-73.19) for Cmax . Mean terminal half-life decreased from 13.39 to 5.11 hours, geometric mean apparent oral clearance increased from 12.27 to 41.38 l h-1 , whereas median time to Cmax remained similar (1.50 vs. 1.25 hours) in the presence of rifampin. All adverse events (n = 29) were mild in severity and resolved by the end of the study. CONCLUSIONS: Co-administration of rifampin expectedly decreased glasdegib AUCinf and Cmax by ~70% and ~35%, respectively. These results will help to formulate recommendations for dosing strategies in combination with CYP3A inducers in situations where co-administration may be necessary. (clinicaltrials.gov identifier: NCT02430545).
引用
- Shaik MN, Hee B, Wei H, et al. Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers. Br J Clin Pharmacol. 2018. PMID: 29488303. doi:10.1111/bcp.13568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。